We present the results of a prospective, randomised study comparing PBPC and BM focusing on engraftment, acute and chronic GVHD and survival. Forty patients with haematological malignancies received HLA-identical sibling BM (group A) or PBPC (group B). Evaluable patients were 19 (A) and 18 (B). Median age was 35 (17-56) in A and 29.5 (9-51) in B. Conditioning was mainly Bu-Cy2; GVHD prophylaxis was CSA-MTX. PBPC were harvested after 5 days of G-CSF 10 g/kg/day. Median days for an ANC Ͼ0.5 ؋ 10 9 /l was 18 (13-30) in A and 16 (11-25) in B (P = 0.10). Platelets Ͼ20 ؋ 10 9 /l occurred at ؉17 (10-40) in A and ؉12 (9-36) in B (P = 0.01). The probability of у2 grade a-GVHD was 19% (A) and 27% (B) (P = 0.53). The probability of all grade c-GVHD was 70% with BM. In spite of the small number of patients in group B (PBPC), our data suggest the great majority of them will have c-GVHD (P = 0.08); extensive disease was present in 50 and 100%, respectively (P = 0.05). The estimates of overall survival for A and B at 1000 days are 51 and 47%, respectively (P = 0.67); DFS at 1000 days are 52 and 58%, respectively (P = 0.50). PBPC resulted in faster platelet engraftment. The incidence of acute and chronic GVHD was similar in both groups, but the severity of c-GVHD was higher with PBPC. No differences in survival and DFS have been observed to date.
Bone marrow (BM) has been the standard source of cells to rescue lympho-haematopoiesis after myeloablative therapy but recently allogeneic peripheral blood progenitor cells (PBPC) have been replacing bone marrow for autologous transplants. [1] [2] [3] [4] Moreover, pilot and retrospective studies suggest that HLA-identical PBPC can also restore haemopoiesis without an increase in the incidence or severity of acute graft-versus-host-disease (a-GVHD). 5 ised by growth factors have shown advantages over bone marrow cells in terms of ease of collection and favourable kinetics of haematopoietic reconstitution leading to accelerated platelet and neutrophil recovery. [5] [6] [7] [8] [9] The use of rhG-CSF for mobilisation of progenitor cells into the circulation is safe and has already been extensively utilised in autologous transplantation, with a side-effect profile that makes it a reasonable option for normal donors. 5, 10, 11 The most important problems related to the PBPC transplant seem to be those associated with incidence and severity of chronic GVHD (c-GVHD). Data from Seattle and other groups suggest that the incidence of c-GVHD may be higher after PBPC than after marrow grafting. [12] [13] [14] [15] The hazard of developing clinical extensive c-GVHD by 2 years was 2.37 times higher among PBPC than marrow recipients. 12 However, few formal comparisons have been made between the outcomes of patients receiving HLA-identical allogeneic PBPC transplants and those receiving BM transplants. 9 Randomised studies have been undertaken by many centres, but no published data have been available to date. Therefore, following a previous pilot study 5 we began a controlled, randomised study aiming at comparing primarily survival, and secondly, engraftment kinetics, incidence and severity of acute and chronic GVHD in allogeneic bone marrow transplantation for haematological malignancies.
Patients and methods

Eligibility criteria
This study was a prospective randomised, phase III trial performed in a single institution. It began in February 1995 and closed in October 1997. All patients had at least 100 days of follow-up after transplantation. Eligibility criteria for entry into the study were age between 10 and 60 years, haematological malignancy as primary disease and HLAidentical sibling donors. A detailed explanation about the procedure and its potential complications were given to patients and donors. Informed consent was obtained using protocols and forms according to our institution regulations. Patients, donors and treatment characteristics are shown in Table 1 . M = male; F = female; CML = chronic myeloid leukaemia; CP = chronic phase; AML = acute myeloid leukaemia; rel = relapse; ALL = acute lymphoblastic leukaemia; CR = complete remission; MDS =myelodysplastic syndrome; RA = refractory anaemia; AP/BC = accelerated phase/blastic crisis; MM = multiple myeloma; NHL = non-Hodgkin's disease; RAEB = refractory anaemia with excess of blast; Bu (16) = busulfan (16 mg/kg); Cy (120) = cyclophosphamide (120 mg/kg); VP-16 = etoposide (40 mg/kg); TBI = total body irradiation; CSP = cyclosporine; MTX = methotrexate; Pred = prednisone.
Donors
All PBPC donors received rhG-CSF (Granulokine; Roche, SP, Brazil) by subcutaneous injection (10 g/kg daily for 5 consecutive days). Apheresis was performed on day 5 of G-CSF administration. Day 5 rhG-CSF donor administration was timed to coincide with day 0 of the allograft recipient. Leukaphereses were performed by a Dideco Vivacell (Mod. BT-798 CE/A; Mirandola, Italy) continuous flow blood cell separator using a standard leukocyte apheresis program. The collection usually lasted 3-5 h and a vein-to-vein technique was used to avoid use of an indwelling catheter. After collection, the apheresis product was infused into recipients immediately. A goal of this study was to collect and infuse a minimum of 2 × 10 8 of total mononuclear cells (TMNC). 16 Bone marrow was obtained from donors by standard methods. 17 Day 0 for the recipient was defined as the day of BM or PBPC infusion.
A summary of pre-treatment preparative regimens and GVHD prophylaxis is shown in Table 1 . No growth factors were used after transplantation.
Evaluations and definitions
PBPC and BM were analysed for CD34
+ cells and T cell subsets by flow cytometry as previously described. 18 Monoclonal antibodies were obtained from Becton Dickinson Immunocytometry Systems (San Jose, CA, USA).
CD34-positive cells were quantified using a modification of the method described by Sutherland et al. 18 In this modification, the antibody CD14/FITC was used instead of CD45 to exclude myeloid/monocytic cells contaminating the CD34/PE-positive population defined as CD14 negative and presenting a low side scatter.
T cell subsets were analysed by the whole blood lyse/wash method using the monoclonal antibodies CD3-FITC/CD4-PE, CD3-FITC/CD8-PE and CD4-FITC/CD8-PE. All data were collected and analysed in the FACscalibur flow cytometry equipment (Becton Dickinson), using the software Cell Quest.
Neutrophil engraftment was defined as the first of 2 consecutive days with an absolute neutrophil count (ANC) Ͼ0.5 × 10 9 /l following a post-transplant nadir. Platelet engraftment was defined as the first of 7 consecutive days with a platelet count Ͼ20 × 10 9 /l without platelet transfusion. Engraftment was also documented by marrow aspiration, biopsy and cytogenetics.
Assessment and grading of a-GVHD and c-GVHD were made using the Glucksberg 19 and Shulman criteria, 20 respectively. Supportive care was provided in private rooms equipped with HEPA filters. Irradiated red blood cell and platelet transfusions, as well as broad-spectrum antibiotics together with anti-fungal agents, were given whenever indicated. Ceftazidime was started as soon as the neutrophil count dropped below 0.5 × 10 9 /l and changes were made as indicated by cultures and clinical course, keeping the patient on antibiotics until the granulocyte count reached 1.0 × 10 9 /l. All patients received ganciclovir (5 mg/kg/day 3 times a week) after marrow recovery as cytomegalovirus (CMV) infection prophylaxis until day 75 post-transplant. Nutritional support, including total intravenous nutrition, was provided to assure an adequate nutritional balance.
Statistical methods
Analysis was based on status of the patients on 1 February 1998. Our main objective was to compare overall survival and then compare objective response rates, disease-free survival and toxicity. Overall survival (OS) in both groups was measured from the date of randomisation to the date of death or last follow-up evaluation. Disease-free survival only applies to patients who achieved a complete remission. Duration was calculated from the time of CR assessment to the date of relapse or last follow-up evaluation confirming freedom from disease. All data were analysed with descriptive statistical methods. Probability of events (neutrophil and platelet recovery, a-GVHD, c-GVHD) and survival curves were analysed using Kaplan-Meier 21 product limit estimates, and groups were compared using the log-rank test or Breslow's test with SPSS software version 7. 
Donors
All donors received the proposed dose of rhG-CSF. Leukapheresis procedures and rhG-CSF were generally well tolerated. The median total blood processed was 12.0 l (9.4-28.5). The median white blood cell count on day 5 of rhG-CSF was 31.7 × 10 9 /l (12.3-62.5). No side-effects with rhG-CSF were observed in seven of 18 donors (39%). Mild bone pain occurred in eight out of 18 donors (44%) whereas two of 18 (11%) experienced headache. All donors showed a decrease in platelet counts after apheresis. The median pre-apheresis platelet count was 239.5 × 10 9 /l (149.0-369.0) and post-apheresis it was 119.0 × 10 9 /l (58.0-217.0) (P Ͻ 0.0001). Seven of 18 donors (39%) had platelet reductions below 100 × 10 9 /l. However, no bleeding episodes occurred. There were no relevant changes in hematocrit. No significant problems were seen during apheresis despite the large volume of blood that was processed.
Comparability of PBPC and BM groups
As shown in Table 1 , PBPC and BM groups were well matched for diagnosis, age, phase of disease and treatment.
Recipients of allogeneic PBPC received a median of 5.5 × + cells (P = 0.47), were significantly higher in the PBPC group (Table 2) .
Engraftment and transfusion requirements
Parameters of engraftment and transfusion requirements are shown in Table 3 . One patient transplanted with PBPC died and one developed disease progression before reaching neutrophils Ͼ0.5 × 10 9 /l. One patient transplanted with BM had primary engraftment failure. Among those who did reach an ANC of 0.5 × 10 9 /l, the median day to achieve such a count was 16 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) for recipients of PBPC and 18 (13-30) for recipients of BM. The median period to achieve a count of Ͼ0.5 × 10 9 /l neutrophils was not significantly shorter for patients receiving PBPC (P = 0.15) (Figure 1) .
One patient receiving PBPC developed progression of his primary disease before reaching platelet transfusion independence. Two patients in each group died before reaching platelet transfusion independence. One patient in the BM group was not evaluable due to primary engraftment failure. The median day to achieve platelet independence was day 12 (9-36) for the PBPC group and There were no engraftment failures in the PBPC group, but one primary failure was seen in the BM group. This patient did not respond to G-CSF and was therefore treated with mobilised PBPC obtained from the original BM donor. Engraftment of neutrophils occurred on day 24, and platelets on day 28 after infusion. The patient developed extensive c-GVHD on day 348 but is alive and well receiving cyclosporin and prednisone.
Acute and chronic GVHD
As shown in Table 4 , the incidence of grades 2 to 4 acute GVHD was four out of 15 (26.6%) evaluable PBPC compared to three out of 16 (18.7%) patients who were transplanted with BM (P = 0.40). Grades 3 to 4 acute GVHD occurred in two out of four and in two out of three patients receiving PBPC or BM, respectively. The probabilities of developing grades 2 to 4 acute GVHD were 27% for Table 4 Incidence of a-GVHD and c-GVHD patients transplanted with PBPC and 19% for patients transplanted with BM (P = 0.53) (Figure 3) . Clinical chronic GVHD of all grades developed in 10 out of 14 (71.4%) evaluable PBPC recipients and in eight out of 15 (53.3%) BM recipients (P = 0.53) ( Table 4) . Table 5 shows the areas involved by c-GVHD. No difference was observed, except for more mouth involvement in the PBPC group (P = 0.03) ( Table 5 ). Although the number of evaluable cases receiving PBPC is small, our data suggest that the great majority will have c-GVHD of all grades, whereas for patients transplanted with BM the probability is 70% (P = 0.08) (Figure 4 ). All patients in the PBPC group developed extensive chronic GVHD while four out of eight (50%) developed extensive chronic GVHD in the BM group (P = 0.02).
Causes of death
As shown in Table 6 , five out of eight (62.5%) of the cases receiving PBPC died of transplant-related complications as compared to seven out of nine (77.8%) who received BM. There were two deaths from bacterial infection in the PBPC group and one in the BM group. One death occurred from gastric-intestinal CMV and one from hepatic veno-occlusive disease (VOD). There was one case of haemorrhagic cystitis in the BM group. No deaths due to CMV, VOD or haemorrhage were seen in the PBPC group. One patient in each group died of a-GVHD and two patients in each group died of c-GVHD. In both groups, all relapsed or progressing patients died, three out of eight patients (37.5%) in the group receiving PBPC and two out of nine patients (22.2%) in the BM group.
Relapse
Among patients transplanted with PBPC, two out of 18 (11%) patients have relapsed and one out of 18 (5.5%) had early disease progression. In patients transplanted with BM, two out of 19 (10.5%) have relapsed.
Survival
Ten out of 18 (55.5%) patients who received PBPC have survived after a median of 335 days (120-1079). In the BM group 10 out of 19 (52.6%) have survived after a median of 631 days (281-1044). The estimates of overall survival for the PBPC and BM groups at 1000 days are 47 and 51%, respectively (P = 0.67); DFS for the PBPC and BM groups at 1000 days are 58 and 52%, respectively (P = 0.50) (Figures 5 and 6 ).
Discussion
This study was designed taking as base a pilot project carried out in our Unit in 1994 that used allogeneic PBPC transplantation in a group of patients with haematological Table 6 Causes of death
PBPC (%) BM (%)
Early progression 1 (12. malignancies. 5 In this study, PBPC were obtained by a single apheresis. Therefore, this procedure was maintained in the present trial.
The aim of the previous pilot project was to demonstrate feasibility of the procedure, considering acute GVHD incidence and severity, engraftment kinetics and morbidity. Results of that pilot study and data in the literature comparing standard BMT results, showed faster engraftment, and shorter hospital stay for PBPC. Also, incidence and severity of GVHD and morbidity were comparable between the two groups. The current data obtained by this prospective and randomised study seem to confirm our preliminary data and those obtained by other authors. [5] [6] [7] 9 The first important observation was similar engraftment for both groups, except for platelet recovery, which was faster in the PBPC group (P = 0.01). In spite of the difference not being statistically significant, the number of platelet and red cells transfused was lower in the PBPC group. Procedure-related complications were also similar in numbers. We observed no cases of primary or late engraftment failures in PBPC group. In the BM group, however, one patient had primary failure of engraftment. He received mobilised PBPC from the same BM donor, and attained stable engraftment.
Collection of PBPC was well tolerated by donors. The dose of rhG-CSF was 10 g/kg for 5 days followed by a single leukapheresis with a median blood volume processed of 12 l on day 5. Using this standard procedure we achieved a median of 4.7 × 10 6 /kg CD34 + cells of recipient body weight, which was lower than BM yield (5.2 × 10 6 /kg of recipient). Data from the literature suggest the necessity for at least two leukaphereses to obtain more than 5.0 × 10 6 /kg, 6, 7, 10, 22, 23 which has been associated with a faster engraftment. 24 Data using only one leukapheresis and 10 g/kg/day by 5 days of rhG-CSF, have shown a similar median number of CD34 + cells (4.6 × 10 6 /kg) compared to our results. 25 These data, however, suggest that our mobilisation protocol was adequate, as engraftment in the PBPC group was faster with these PBPC numbers. In addition, long-term follow-up showed stable engraftment in all patients. However, the number of aphereses can be increased if necessary to obtain a higher number of CD34 + cells. Despite the similarity in CD34
+ cell numbers infused in the BM and PBPC groups, the different kinetics can be explained by the biological properties of PBPC. In autologous transplantation with PBPC where patients were mobilised with cyclophosphamide and rhG-CSF, the PBPC were insensitive to cell-cycle restraint imposed by contact with marrow-derived stromal cells, which therefore did not reduce the proportion of progenitors participating in neutrophil production. 26 Moreover, filgrastim increases numbers of circulating megakaryocyte progenitors in PBPC donors, and this has also been associated with accelerated platelet recovery in recipients of autologous filgrastim-stimulated PBPC. 7 One of the greatest concerns with allogeneic PBPC transplantation is the possibility of increasing incidence and severity of GVHD due to the high number of T cells present in the graft. 8 However, neither experimental nor clinical data exist to show a correlation between the occurrence of acute GVHD and T cell number, in either BM 8 or PBPC 7 transplants. The low incidence of acute GVHD in PBPC transplant recipients may be attributed to G-CSF-induced preferential differentiation of T helper cells into Th2 rather Th1 cells, resulting in PBPC grafts with relatively few Th1, which have been implicated in the pathogenesis of acute GVHD, 27 or the large number of monocytes in PBPC grafts that suppress T cells. 28 In our study we did not find any difference in the incidence and severity of acute GVHD in the PBPC group compared to the BM transplant group. The incidence of chronic GVHD was similar but we observed a trend to developing total c-GVHD in the PBPC group (P = 0.08). Indeed, comparing the severity of c-GVHD in both groups, all PBPC patients developed extensive chronic GVHD compared to 50% of patients in the BM group (P = 0.02). A high incidence and severity of chronic GVHD after PBPC transplantation has already been reported by others. [12] [13] [14] [15] In our study, involvement of various tissues was similar between groups, except for a higher incidence of oral mucosal lesions in the PBPC group (P = 0.03). Previous data from our group suggest that patients with more severe lesions of the labial salivary glands will have shorter survivals; 29 data suggest that the polarisation of Th1→Th2 may wane or that the monocytes may die within the first months after grafting. 12 Although monocytes and T cell counts are higher in PBPC than in marrow recipients during the first 2 months, thereafter the monocyte counts are similar, whereas the T cells counts were higher in the PBPC recipients for at least 6 months. 30 This mechanism may be associated with the higher incidence of c-GVHD. Chronic GVHD has been associated with a low incidence of leukaemia relapse. 31, 32 Therefore, allogeneic PBPC transplantation could also be associated with a lower incidence of relapse. 14, 33 In the current study we could not confirm this observation. Relapses were few and similar in number in both groups, which may reflect the small number of patients analysed.
Mortality was similar in both groups and the majority of deaths were procedure-related. Also, the higher frequency of extensive chronic GVHD in the PBPC group correlated neither with death nor with worsening of life quality. It is still unclear whether the benefits of fast engraftment or a possible graft-versus-leukaemia reaction outweigh any adverse effects such as c-GVHD. 6, 12 In patients at high risk of relapse, developing of c-GVHD could have beneficial effects. 6 We believe that allogeneic PBPC transplants should not be used routinely, but only in prospective randomised trials, until issues regarding c-GVHD and relapse are clarified.
